On demand sessions
All pre-recorded lectures will be available on-demand starting 15 October, 09:00 CET (date and time to be confirmed)
|
Patient advocacy session: Managing your Mind: stress, anxiety, depression and resilience Chairs: Shirley A. Mertz, US and Claire Myerson UK |
|
|
How to diagnose and manage stress, anxiety and depression in ABC patients. What is resilience and how to develop it? Luzia Travado, PT |
30 min |
|
Patient Experiences Panel Panel of experts: Theresa Wiseman, UK – Shani Paluch Shimon, IL Gloria Okwu, NG – Boon Lui Sew, MY - Nelly Perez, MX |
40 min |
|
|
|
|
Patient advocacy session: Can big data and artificial intelligence help ABC patients? Chairs: Renate Haidinger, DE and Kim Sabelko, US |
|
|
Technology-based PROMs and AI-driven decision support: the example of CANKADO Timo Schinköthe, DE |
15 min |
|
Emerging Pathomics – The role of AI pathology Frédérique Penault-Llorca, FR |
15 min |
|
A new tool: BCNA Symptom tracker Kirsten Pilatti, AU |
15 min |
|
Advancing ABC management through AI/Big data Fatima Cardoso, PT |
15 min |
|
|
|
|
Patient advocacy session: Oncobrain: Not an excuse but a common reality Chairs: Ginny Mason, US and Elizabeth Bergsten-Nordstrom, SE |
|
|
What is it? How do you know you have it? Ginny Mason, US and Elizabeth Bergsten-Nordstrom, SE |
30 min |
|
How to diagnose and to manage Onco-brain? Berta Sousa, PT |
30 min |
|
|
|
|
Patient advocacy session: Global Inequalities in access to clinical trials Chairs: Eva Schumacher, DE and Runcie C.W. Chidebe, NG |
|
|
Global inequalities in access to ABC clinical trials in LMICs: Challenges and opportunities – the African perspective |
15 min |
|
Global inequalities in access to ABC clinical trials in LMICs: Challenges and opportunities – the Latin-American perspective |
15 min |
|
Patient Experiences Panel Panel of experts (TBC) : Alexandru Eniu, CH – Gertrude Nakigudde, UG Bertha Aguilar, MX – Ranjit Kaur, MY – Bishal Gyawali, CA Dany Habr, US – Carlos Barrios, BR – Funmi Olopade, US |
40 min |
|
Challenges on evaluating patients with ABC Chairs: Christoph Thomssen, DE and Frédéric E. Lecouvet, BE |
|
|
Re-defining progressive disease: oligo-progression, pseudo-progression, endocrine flare Karen Gelmon, CA |
15 min |
|
How to act in discordant biomarker results (primary vs mets vs other mets) Aleix Prat, ES |
15 min |
|
Optimal timing and interval of imaging for ABC (clinical practice & trials) George W. Sledge, US |
15 min |
|
Is it time to change the follow-up guidelines for early BC - aka - is it worthwhile to detect metastatic disease earlier? Ann H. Partridge, US |
15 min |
|
Best abstract presentations Chairs: Alberto Costa, IT/CH and Renate Haidinger, DE |
|
|
Measuring knowledge, skills and confidence in metastatic breast cancer nursing: The Cancer Nurse Self-Assessment Tool for Metastatic Breast Cancer (CaN-SAT-MBC) |
10 min |
|
From early to metastatic breast cancer: A systematic review and meta-analysis of distant recurrence rates |
10 min |
|
A national study of the experiences, information needs and attitudes to clinical research of patients living with secondary breast cancer in the UK |
10 min |
|
Emotional distress, brain functioning, social well-being and biobehavioral processes in metastatic breast cancer patients: outcomes of the DistressBrain Project |
10 min |
|
The standards in 2021 Chairs: Elzbieta Senkus, PL and Bertha Aguilar, MX |
|
|
Current standard of care for HER2+ ABC Sandra M. Swain, US |
15 min |
|
Current standard of care for Triple Negative ABC Giuseppe Curigliano, IT |
15 min |
|
Current standard of care for ER+/HER2 neg ABC Nadia Harbeck, DE |
15 min |
|
Biology Medley Chairs: William J. Gradishar, US and Sung-Bae Kim, KR |
|
|
Beyond overexpression/amplification of HER2 Giuseppe Viale, IT |
15 min |
|
Predictive biomarkers for immune-checkpoint inhibitors: lost or found? Frédérique Penault-Llorca, FR |
15 min |
|
Biomarkers of resistance/response to endocrine-based therapy. What's ready for clinical practice? Nicholas Turner, UK |
15 min |
|
Hereditary breast cancer: which markers besides gBRCA? Shani Paluch-Shimon, IL |
15 min |
|
Who's caring for the carers? Chairs: Olivia Pagani CH, Lesley Fallowfield UK and Barbara Wilson, UK |
|
|
Spouses, Children, Parents: psychological issues Luzia Travado, PT |
15 min |
|
What do carers need to care Theresa Wiseman, UK |
15 min |
|
Health Care Providers: Compassionate fatigue Michal Braun, IL |
15 min |
|
What's new in the management of inoperable inflammatory (IBC) and locally advanced breast cancer (LABC) Chairs: Ginny Mason, US and Daniel A. Vorobiof, US |
|
|
Have we improved our knowledge about biology? Sofia D. Merajver, US |
15 min |
|
Systemic management of inoperable inflammatory breast cancer: any news? Hamouda Boussen, TN |
15 min |
|
Optimal loco-regional management Maria Joao Cardoso, PT |
15 min |
|
What should be updated in the ABC guidelines for systemic therapy for inoperable LABC and IBC? Joseph Gligorov, FR |
20 min |
|
From manageable to tolerable: focus on side effects Chairs: Shinji Ohno, JP and Eva Schumacher, DE |
|
|
Pneumonitis/Interstitial Lung Disease (ILD) Hope S. Rugo, US |
15 min |
|
Immune-related toxicity Carlos H. Barrios, BR |
15 min |
|
Preventing and treating cardiotoxicity Evandro de Azambuja, BE |
15 min |
|
The role of cannabis for ABC patients Matti S. Aapro, CH |
15 min |
|
Oligometastatic disease and specific sites of metastases Chairs: Shani Paluch-Shimon, IL and Ranjit Kaur, MY |
|
|
Re-defining oligo-metastatic disease and its systemic management Prudence A. Francis, AU |
15 min |
|
SBRT and new radiotherapy techniques for metastatic disease Birgitte V. Offersen, DK |
20 min |
|
Optimal management of peritoneal carcinomatosis and ascites Nagi El Saghir, LB |
15 min |
|
Drug development for ABC Chairs: Jonas Bergh, SE and Kirsten Pilatti, AU |
|
|
Antibody-drug conjugates: delivering chemotherapy at the tumor's doorsteps Javier Cortés, ES |
15 min |
|
Newer therapeutic options for triple negative ABC Rebecca A. Dent, SG |
15 min |
|
New drug interactions and consequences Alessandra Gennari, IT |
15 min |
|
Is the maximum tolerated dose (MDT) still the optimal goal for cancer drugs? Larry Norton, US |
15 min |
|
Managing ABC during a pandemic Chairs: Elizabeth Bergsten-Nordström, SE and Binghe Xu, CN |
|
|
Lessons learned from COVID-19 Laura Biganzoli, IT |
15 min |
|
The ABC of vaccination for advanced breast cancer patients Alexandru Eniu, CH |
15 min |
|
Strengths and limitations of tele-medicine for ABC patients Fran Boyle, AU |
15 min |
SPONSORED SATELLITE SYMPOSIA (on-demand)
|
Daiichi Sankyo/AstraZeneca sponsored satellite symposium: A team approach to the treatment of patients with HER2-postive metastatic breast cancer |
|
|
Lilly sponsored satellite symposium: Beyond the doors of MDT meeting: impact on HR+HER2- breast cancer patients. |
|
|
Novartis sponsored satellite symposium: What matters to patients with HR+ HER2– ABC: Expanding options for living better for longer |
|
|
Pfizer sponsored satellite symposium: Raising awareness of underserved patient populations: Solutions from the real world |
|
|
Seagen sponsored satellite symposium: Multidisciplinary team perspectives on the evolving treatment landscape in HER2+ MBC |
|
Sponsored satellite symposia programmes available here.